Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.47 |
| ▸ | SNCA | P37840 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27553747 | 0.86 | GAA (0.53) | MAPK1NPSR1GAAHTTMAPT | |
| SCHEMBL27618612 | 0.82 | MAPK1 (0.69) | MAPK1NPSR1GAAHTTMAPT | |
| SCHEMBL5175720 | 0.80 | MAPK1 (0.77) | MAPK1NPSR1GAAHTTMAPT | |
| SCHEMBL5390822 | 0.77 | KDM4E (0.60) | MAPK1NPSR1GAAHTTMAPT | |
| SCHEMBL11264402 | 0.76 | MAPK1 (0.85) | MAPK1NPSR1GAAHTTMAPT | |
| SCHEMBL6846139 | 0.76 | MAPK1 (1.00) | MAPK1NPSR1GAAHTTMAPT | |
| SCHEMBL10727439 | 0.76 | MAPK1 (0.81) | MAPK1NPSR1GAAHTTMAPT | |
| SCHEMBL10953243 | 0.72 | HSD17B10 (0.62) | MAPK1NPSR1GAAMAPTKDM4E | |
| SCHEMBL7039446 | 0.72 | HTT (0.55) | MAPK1NPSR1GAAHTTMAPT | |
| SCHEMBL19785375 | 0.72 | HSP90AA1 (0.56) | NPSR1MAPTKDM4ETDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425279-A4 | METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES | SEARLE LLC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050090543-A1 | Method for the preparation of tetrahydrobenzothiepines | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | US | disclosed |
| EP-1448546-A4 | NOVEL MONO- AND DI-FLUORINATED BENZOTHIEPINE COMPOUNDS AS INHIBITORS OF APICAL SODIUM CO-DEPENDENT BILE ACID TRANSPORT (ASBT) AND TAUROCHOLATE UPTAKE | SEARLE LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6794544-B2 | APICAL SODIUM CO- DEPENDENT BILE ACID TRANSPORTER (ASBT) INHIBITORS | PHARMACIA CORPORATION | 2004-09-21 | — | — | US | disclosed |
| US-20040176438-A1 | Novel mono- and di-fluorinated beozothiepine copmunds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake | G.D. SEARLE, LLC | 2004-09-09 | — | — | US | disclosed |
| EP-1448546-A1 | NOVEL MONO- AND DI-FLUORINATED BENZOTHIEPINE COMPOUNDS AS INHIBITORS OF APICAL SODIUM CO-DEPENDENT BILE ACID TRANSPORT (ASBT) AND TAUROCHOLATE UPTAKE | G.D. Searle LLC (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040110761-A1 | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | G.D. SEARLE LLC | 2004-06-10 | — | — | US | disclosed |
| EP-1425279-A2 | METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES | G.D. Searle LLC (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6740663-B2 | ANTIHYPERLIPIDEMIC AGENTS | G.D. SEARLE, LLC | 2004-05-25 | — | — | US | disclosed |
| US-20040082647-A1 | Method for the preparation of tetrahydrobenzothiepines | G.D. SEARLE, LLC | 2004-04-29 | — | — | US | disclosed |
| US-20030232834-A1 | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | KELLER BRADLEY T (US) | 2003-12-18 | — | — | US | disclosed |
| WO-2003022804-A9 | METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES | SEARLE LLC (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030199515-A1 | Method for the preparation of crystalline tetrahydrobenzothiepines | G.D. SEARLE, LLC (US) | 2003-10-23 | — | — | US | disclosed |
| US-6586434-B2 | Method for the preparation of tetrahydrobenzothiepines | G.D. SEARLE, LLC | 2003-07-01 | — | — | US | disclosed |
| WO-2003040127-A1 | NOVEL MONO- AND DI-FLUORINATED BENZOTHIEPINE COMPOUNDS AS INHIBITORS OF APICAL SODIUM CO-DEPENDENT BILE ACID TRANSPORT (ASBT) AND TAUROCHOLATE UPTAKE | G.D. SEARLE LLC (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003022804-A2 | METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES | G.D. SEARLE LLC (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-1286984-A2 | METHOD FOR THE PREPARATION OF TETRAHYDROBENZOTHIEPINES | Pharmacia Corporation (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020061888-A1 | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | G.D. SEARLE LLC | 2002-05-23 | — | — | US | disclosed |
| US-20020032329-A1 | Method for the preparation of tetrahydrobenzothiepines | G.D. SEARLE LLC | 2002-03-14 | — | — | US | disclosed |
| WO-2001068637-A2 | METHOD FOR THE PREPARATION OF TETRAHYDROBENZOTHIEPINES | PHARMACIA CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110761-A1 | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | SLC10A1, HMGCR, SLC10A2 | MAPK1 3790/4885NPSR1 2459/4885GAA 670/4885 |
| US-20030199515-A1 | Method for the preparation of crystalline tetrahydrobenzothiepines | TPMT, MPST, SULT1A1 | MAPK1 3866/4885NPSR1 3308/4885GAA 2967/4885 |
| US-20030232834-A1 | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | TOP2A, TOP2B, TYMP | MAPK1 2895/4885NPSR1 4218/4885GAA 996/4885 |
| US-20020032329-A1 | Method for the preparation of tetrahydrobenzothiepines | TMT1A, THOP1, BBOX1 | MAPK1 3514/4885NPSR1 3049/4885GAA 3430/4885 |
| US-20040176438-A1 | Novel mono- and di-fluorinated beozothiepine copmunds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake | SLC10A1, SLC10A2, ABCB11 | MAPK1 3437/4885NPSR1 3233/4885GAA 1008/4885 |
| US-20020061888-A1 | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | SLC10A1, HMGCR, SLC10A2 | MAPK1 3892/4885NPSR1 2872/4885GAA 298/4885 |
| US-20050090543-A1 | Method for the preparation of tetrahydrobenzothiepines | TMT1A, THOP1, BBOX1 | MAPK1 3514/4885NPSR1 3049/4885GAA 3430/4885 |
| US-20040082647-A1 | Method for the preparation of tetrahydrobenzothiepines | TMT1A, THOP1, BBOX1 | MAPK1 3514/4885NPSR1 3049/4885GAA 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.